MoneyAM

Summit Corporation Share Price (SUMM)

0.00 0.00 (0.00%) delayed: 3:18AM BST
Bid price 0.00 Open price 0.00
Ask price 0.00 Prev close 106.50
High price 0.00 Spread 0.00%
Low price 0.00 Volume 0

Register now for FREE live Summit Corporation share prices, Summit Corporation stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Summit Corporation Level 2 Data, indepth research tools and investor commentary for Summit Corporation (SUMM) and other London Stock Exchange equities.

Summit Corporation Share Price Chart

Advanced Charts >>

Register now for FREE Summit Corporation share price charts

Summit Corporation Share Price Information

Name Summit Corporation Epic SUMM
Sector Pharmaceuticals & Biotechnology ISIN GB00BN40HZ01
Activites Summit plc (formerly VASTox plc) is a UK based drug discovery company with a major focus on developing new therapeutics from its iminosugar drug discovery platform. Summit believes iminosugars are the key to gaining access to several disease mechanisms where classical drugs have had little success, and thus offer a major opportunity for the discovery and development of new medicines. Carbohydrates (sugars) play critical roles in maintaining correct functioning of many normal processes in healthy individuals and errors in carbohydrate recognition or modification can lead to malfunction in cells resulting in disease. Iminosugars have the potential to mimic carbohydrates or to interact with processes which manipulate carbohydrates to modify activity or to correct aberrant function. Additionally, iminosugars, due to their sugar-like properties, have important effects when interacting with many other unexploited therapeutic targets. Index n/a

Summit Corporation Key Numbers

Latest Share Price (p) 0.00 Net Gearing (%) -2.43
Market Capitalisation (£m) 874.61 Gross Gearing (%) 28.19
Shares in issue (m) 821.23 Debt Ratio 0.00
P/E Ratio -71.48 Debt-to-Equity Ratio 0.00
Total dividends per share (p) 0.00 Assets / Equity Ratio 1.39
Dividend Yield (%) 0.00 Price to book value 183.74
Dividend cover (x) 0.00 ROCE -1.46
Earning per share (p) -1.49 EPS Growth (%) 0.00
52 week high / low 143.50 / 4.63 DPS Growth (%) n/a

Summit Corporation Director Deals

Dec.Date Type Director Pos No. of Shares
26/07/2013 PLAC Glyn Edwards CEO 600,000
26/07/2013 PLAC Dr Frank Armstrong CH 50,000
26/07/2013 PLAC Barry Price NED 500,000
26/07/2013 PLAC Jim Mellon NED 20,000,000
14/06/2012 BUY George Elliott RES 150,000

More Summit Corporation Director Deals >>

Summit Corporation Company News

15:10 18/07/2014

Summit Corporation PLC : Update on Capital Reor...

Summit Corporation PLC : Update on Capital Reorganisation Timetable body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Summit Corporation plc ('Summit' or the 'Company') UPDATE ON CAPITAL...

07:01 16/07/2014

Summit Corporation PLC : Award of Share Options

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Summit Corporation PLC : Award of Share Options Summit Corporation plc ('Summit' or the 'Company') AWARD OF SHARE OPTIONS Oxford, UK,...

07:30 09/07/2014

Summit says FDA grants QIDP designation to SMT19969

Summit Corp, a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy and C. difficile infection (CDI), said the US FDA has designated the Company's novel antibiotic SMT19969 for the treatment of CDI as a Qualified Infectious Disease Product (QIDP). The QIDP...

More Summit Corporation Company News >>

Register now for FREE Summit Corporation company news

Summit Corporation Share Price Discussions

19 days ago

Summit Corporation PLC (SUMM)

http://www.summitplc.com/ Summit is an Oxford, UK based drug discovery company developing novel drug candidates to treat areas of high unmet medical need. Our strategy has evolved to focus on the development of two high-value clinical-stage programmes that target the fatal genetic disease...

more than 1 year ago

Summer Bonanza is upon us.......... (SUMM)

OK folks it's mid March and spring is upon us. Time to start looking ahead, the mkts have had a bit of a setback, is this the healthy correction that's been spoken about for so long or is it a buying opportunity on the road to new highs? Who knows, not me for sure, if I did I'd tell ya'll...

Register now for FREE Summit Corporation share price discussions